Skip to main content
. Author manuscript; available in PMC: 2014 Mar 28.
Published in final edited form as: Cell Stem Cell. 2013 Jan 17;12(3):316–328. doi: 10.1016/j.stem.2012.12.011

Figure 7.

Figure 7

a) Representative TUNEL staining of BC-engrafted bone marrow following treatment with vehicle or sabutoclax. b) Relative engraftment of normal and BC progenitors in bone marrow following vehicle and sabutoclax treatment (5mg/kg). Normal: vehicle n=6, sabutoclax n=6. BC: vehicle n=26, sabutoclax n=27. Graph shows mean +/− SEM and statistical analysis by Mann-Whitney test. c) Fold change of normal stem cell in the bone marrow after treatment with Vehicle (n=8); Sabutoclax 10 mg/kg IV, biweekly for 4 doses (n=8); Dasatinib 50 mg/kg, daily oral gavage, 14 doses total (n=11); combination of Sabutoclax and Dasatinib (n=10). Graph shows mean +/− SEM. d) Fold change of normal stem cell in the spleen after treatment with Vehicle (n=8); Sabutoclax 10 mg/kg IV, biweekly for 4 doses (n=8); Dasatinib 50 mg/kg, daily oral gavage, 14 doses total (n=11); combination of Sabutoclax and Dasatinib (n=10). Graph shows mean +/− SEM. e) Relative engraftment of BC progenitors in spleen, blood and bone marrow following treatment with vehicle (n=9), sabutoclax (1.25mg/kg, n=9), dasatinib (25mg/kg, n=9) and sabutoclax in combination with dasatinib (n=11). Graph shows mean +/− SEM. * p<0.05, ** p<0.01, *** p<0.001 by Kruskal-Wallis test with Dunn's post-hoc analysis. f) Survival of mice following serial transplanted with vehicle-(n=11), sabutoclax- (n=9), dasatinib- (n=9), and combination- (n=13) treated whole bone marrow. Statistical analysis is by log-rank test.